Pregnancy & Lactation : הריון/הנקה

4.6 Fertility, pregnancy and lactation

Fertility:
The use of Etopan may impair female fertility and is not recommended in woman attempting to conceive. ln women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of Etopan should be considered.
Pregnancy:
Drugs which inhibit prostaglandin biosynthesis may cause dystocia and delayed parturition as evidenced by studies in pregnant animals.
Congenital abnormalities have been reported in association with NSAID administration in man; however, these are low in frequency and do not appear to follow any discernible pattern. In view of the known effects of NSAIDs on the foetal cardiovascular system, some inhibitors of prostaglandin biosynthesis have been shown to interfere with the risk of closure of the ductus arteriosus, use in the last trimester of pregnancy is contraindicated. The onset of labour may be delayed and the duration increased with an increased bleeding tendency in both mother and child (see section 4.3).
From the 20th week of pregnancy onward, etodolac use may cause oligohydramnios resulting from foetal renal dysfunction. This may occur shortly after treatment initiation and is usually reversible upon discontinuation. ln addition, there have been reports of ductus arteriosus constriction following treatment in the second trimester, most of which resolved after treatment cessation. Therefore, during the first and second trimester of pregnancy, etodolac should not be given unless clearly necessary. lf etodolac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible. Antenatal monitoring (by ultrasound screening) for oligohydramnios and ductus arteriosus constriction should be considered after exposure to etodolac in its therapeutic dose for more than five days from gestational week 20 onward. Etodolac should be discontinued if oligohydramnios or ductus arteriosus constriction are found.
During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:
-   cardiopulmonary toxicity (premature constriction/closure of the ductus arteriosus and pulmonary hypertension);
-   renal dysfunction (see above);
the mother and the neonate, at the end of pregnancy, to:
-   possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses.
-   inhibition of uterine contractions resulting in delayed or prolonged labour.
Consequently, etodolac is contraindicated during the third trimester of pregnancy (see section 4.3).
Lactation: ln limited studies so far available, NSAIDs can appear in breast milk in very low concentrations.
NSAIDs should, if possible, be avoided when breastfeeding.